Literature DB >> 26955837

Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.

Miguel Luciano Silva1, Leandro Tasso2, Alan Arrieira Azambuja3, Maria Antonia Figueiredo1, Fernanda Gonçalves Salum1, Vinicius Duval da Silva4, Karen Cherubini5,6.   

Abstract

OBJECTIVE: This study aimed to investigate the effect of hyperbaric oxygen therapy (HBOT) on tooth extraction sites in rats treated with bisphosphonate.
MATERIALS AND METHODS: Rats were treated with zoledronic acid, subjected to tooth extractions and allocated into groups: (1) 7 days of HBOT, (2) 14 days of HBOT, (3) 7-day control, and (4) 14-day control. The site of tooth extractions was analyzed by histomorphometry and immunohistochemistry.
RESULTS: On macroscopic analysis, HBOT did not significantly affect bone exposure volume either at 7 or 14 days. On hematoxylin and eosin (H&E) analysis, the 14-day HBOT group showed less non-vital bone compared to both controls and 7-day HBOT group. HBOT significantly lowered expression of vascular endothelial growth factor (VEGF), receptor activator NF-kB ligand (RANKL), bone morphogenetic protein-2 (BMP-2), and osteoprotegerin (OPG) at 7 days, compared to control, whereas at 14 days, there was no significant difference for these variables.
CONCLUSION: HBOT can reduce the amounts of non-vital bone microscopically detected in tooth extraction sites of rats subjected to bisphosphonate therapy. The effect seems to occur in a dose-dependent mode. Further studies are required to clarify the mechanisms accounting for this effect. CLINICAL RELEVANCE: Treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been a challenging task, where the effectiveness of HBOT is controversial. This study reports important effects of HBOT on the maxillae of rats subjected to bisphosphonate treatment, making an important contribution to the knowledge about the applicability of HBOT in BRONJ.

Entities:  

Keywords:  Bisphosphonates; Bone; Hyperbaric oxygen therapy; Osteonecrosis

Mesh:

Substances:

Year:  2016        PMID: 26955837     DOI: 10.1007/s00784-016-1778-3

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  84 in total

1.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

Review 2.  Osteonecrosis of the jaw: who gets it, and why?

Authors:  Ian R Reid
Journal:  Bone       Date:  2008-10-07       Impact factor: 4.398

3.  Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.

Authors:  Yasuyoshi Kobayashi; Toru Hiraga; Akimi Ueda; Liyang Wang; Michiyo Matsumoto-Nakano; Kenji Hata; Hirofumi Yatani; Toshiyuki Yoneda
Journal:  J Bone Miner Metab       Date:  2009-10-31       Impact factor: 2.626

4.  Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.

Authors:  Felix Peter Koch; Christina Merkel; Thomas Ziebart; Ralf Smeets; Christian Walter; Bilal Al-Nawas
Journal:  Clin Oral Investig       Date:  2010-10-12       Impact factor: 3.573

5.  Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.

Authors:  E Nastro; C Musolino; A Allegra; G Oteri; M Cicciù; A Alonci; E Quartarone; C Alati; F S De Ponte
Journal:  Acta Haematol       Date:  2006-12-12       Impact factor: 2.195

6.  Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.

Authors:  Drake W Williams; Cindy Lee; Terresa Kim; Hideo Yagita; Hongkun Wu; Sil Park; Paul Yang; Honghu Liu; Songtao Shi; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  Am J Pathol       Date:  2014-08-28       Impact factor: 4.307

7.  Hyperbaric oxygen attenuates apoptosis and decreases inflammation in an ischemic wound model.

Authors:  Qixu Zhang; Qing Chang; Robert A Cox; Xuemei Gong; Lisa J Gould
Journal:  J Invest Dermatol       Date:  2008-03-13       Impact factor: 8.551

Review 8.  Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws.

Authors:  John J Freiberger
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

9.  Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.

Authors:  Jun Yamada; Nelson H Tsuno; Joji Kitayama; Takeshi Tsuchiya; Satomi Yoneyama; Masahiro Asakage; Yurai Okaji; Yasutaka Shuno; Takeshi Nishikawa; Junichiro Tanaka; Koki Takahashi; Hirokazu Nagawa
Journal:  J Surg Res       Date:  2008-02-29       Impact factor: 2.192

10.  Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw.

Authors:  Paolo Vescovi; Elisabetta Merigo; Marco Meleti; Maddalena Manfredi; Carlo Fornaini; Samir Nammour; Giovanni Mergoni; Amin Sarraj; Jose V Bagan
Journal:  Int J Dent       Date:  2014-02-06
View more
  6 in total

1.  Adverse effects of deoxycholic acid in submandibular glands, submental, inguinal and subplantar regions: a study in rats.

Authors:  Gabriela Alacarini Farina; Valesca Sander Koth; Fábio Luiz Dal Moro Maito; Márcia Rodrigues Payeras; Karen Cherubini; Fernanda Gonçalves Salum
Journal:  Clin Oral Investig       Date:  2022-01-28       Impact factor: 3.573

Review 2.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

3.  Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity.

Authors:  Xue Gong; Wanlu Yu; Hang Zhao; Jiansheng Su; Qing Sheng
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

4.  Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients.

Authors:  Giuliano Vezzani; Silvia Quartesan; Pasqua Cancellara; Enrico Camporesi; Devanand Mangar; Thomas Bernasek; Prachiti Dalvi; Zhongjin Yang; Antonio Paoli; Alex Rizzato; Gerardo Bosco
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

5.  Tetrahedral framework nucleic acid carrying angiogenic peptide prevents bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis.

Authors:  Dan Zhao; Dexuan Xiao; Mengting Liu; Jiajie Li; Shuanglin Peng; Qing He; Yue Sun; Jingang Xiao; Yunfeng Lin
Journal:  Int J Oral Sci       Date:  2022-04-27       Impact factor: 24.897

6.  Hyperbaric Oxygen Therapy Does Not Have a Negative Impact on Bone Signaling Pathways in Humans.

Authors:  Zaida Salmón-González; Javier Anchuelo; Juan C Borregán; Alvaro Del Real; Carolina Sañudo; Maria Teresa García-Unzueta; José A Riancho; Carmen Valero
Journal:  Healthcare (Basel)       Date:  2021-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.